tirzepatide cardiovascular outcomes study and in Patients With Ventricular Tachycardia and Systolic Heart Failure CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN

After month 4, progress typically slows as your body adapts, but continued steady losses of 12 pounds weekly remain achievable with maintained lower caloric intake

Diarrhea is one of the most frequently reported side effects of semaglutide, a GLP-1 receptor agonist used to treat type 2 diabetes and support chronic weight management

WEIGHT LOSS, DIABETES DRUGS CAN CAUSE MOOD CHANGES: WHAT TO KNOW ABOUT BEHAVIORAL SIDE EFFECTS Tirzepatide users also reported a "greater reduction in waist circumference" than those on semaglutide

Closed-Loop Insulin Delivery and Algorithm Patents The integration of CGMs, insulin pumps, and automated dosing algorithms in closed-loop systems creates a category of IP that is part device, part software, part method-of-treatment

Supervised by Dr

Cure houses on-campus startups and established companies